ERAS Jun 2024 2.500 put
| Previous close | 0.0200 |
| Open | 0.0200 |
| Bid | 0.0000 |
| Ask | 0.6500 |
| Strike | 2.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0200 - 0.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
GlobeNewswireErasca to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one
Simply Wall St.Independent Director of Erasca Picks Up 14% More Stock
Investors who take an interest in Erasca, Inc. ( NASDAQ:ERAS ) should definitely note that the Independent Director...
- GlobeNewswire
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional share
